Übersicht – Neue Immuntherapien in der Uro-Onkologie

• Literatur

• 1 Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-133
• 2 Topalian SL, Hodi FS, Brahmer JR et al. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer. N Engl J Med 2012; 366: 2443-2454
• 3 Powles T, Eder JP, Fine GD et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515: 558-562
• 4 Fritsch K, Finke J, Grüllich C. Suppression of granzyme B activity and caspase-3 activation in leukaemia cells constitutively expressing the protease inhibitor 9. Ann Hematol 2013; 92: 1603-1609
• 5 Carl D, Grüllich C, Hering S et al. Steroid responsive encephalopathy associated with autoimmune thyroiditis following ipilimumab therapy. BMC Res Notes 2015; 8: 316